Details of the Drug

General Information of Drug (ID: DMY757D)

Drug Name
Pelacarsen
Indication
Disease Entry ICD 11 Status REF
Cardiovascular disease BA00-BE2Z Phase 3 [1]
Hyperlipoproteinemia 5C80 Phase 3 [2]
Drug Type
Antisense oligonucleotide
Cross-matching ID
TTD ID
DKN63V
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apolipoprotein A messenger RNA (LPA mRNA) TTU9LGY APOA_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04023552) A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05900141) A Single Arm, Open Label Extension (OLE), Multicenter Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Patients With Cardiovascular Disease Who Have Successfully Completed the Apheresis Parent Study.. U.S.National Institutes of Health.
3 Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022 Jul 1;7(7):760-769.